Frank Wu

This inventor holds 14 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: Nanjing Transthera Biosciences Co. Ltd., Transthera Sciences (Nanjing), Inc., Ford Global Technolgoies, LLC. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Wu. Retrieved from https://idiyas.com/inventor/frank-wu-d8p81wlo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 10)

% Patents Active = 78.6

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 18)

Average Co-Inventor Count = 1.6

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Novi, MI (US) (2016 - 2018)
Nanjing, CN (2016 - 2023)

Company Filing History:

7 out of 7

Nanjing Transthera Biosciences Co. Ltd.

patents

4 out of 8

Transthera Sciences (Nanjing), Inc.

patents

3 out of 26,703

Ford Global Technolgoies, LLC

patents

Years Active: 2016-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12751957 - Use of multikinase inhibitor (2026-10-06),

2. 12465601 - Uses of phosphodiesterase inhibitors (2025-11-11),

3. 12371432 - Haloallylamine compounds and application thereof (2025-07-29),

4. 11718620 - Method for treating a cancer mediated by abnormality of multi-kinases (2023-08-08),

5. 11649233 - Halo-allylamine SSAO/VAP-1 inhibitor and use thereof (2023-05-16),

6. 11434248 - PDE9 inhibitor and use thereof (2022-09-06),

7. 11046679 - Indoleamine 2,3-dioxygenase inhibitor and application (2021-06-29),

8. 10889591 - PDE9 inhibitor and use thereof (2021-01-12),

9. 10889586 - Multi-kinase inhibitor compound, and crystal form and use thereof (2021-01-12),

10. 10744139 - Inhibitors of fibroblast growth factor receptor and use thereof (2020-08-18),

11. 10208042 - Multi-kinase inhibitor compound, and crystal form and use thereof (2019-02-19),

12. 10007478 - System and methods for voice-controlled seat adjustment (2018-06-26),

13. 9469228 - Seat climate control assembly and seat employing the same (2016-10-18),

14. 9463747 - Compartment panel assembly and vehicle employing the same (2016-10-11),

Title: Frank Wu: Innovator in Pharmaceutical Sciences

Introduction

Frank Wu is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of pharmaceuticals, holding a total of 14 patents. His work focuses on developing innovative treatments for various medical conditions, particularly those related to heart failure.

Latest Patents

One of Frank Wu's latest patents is centered on the uses of phosphodiesterase inhibitors. This invention discloses a compound represented by a general formula and its pharmaceutically acceptable salts, isomers, and deuterated compounds. The compound has shown promise in treating heart failure diseases by improving heart function in rats, reversing myocardial remodeling, and reducing fibrosis in the marginal zone of infarction. Another notable patent involves haloallylamine compounds, which are relevant in the pharmaceutical field. This invention relates to a halo-allylamine compound and its various forms, including salts and esters. The patent outlines its application in preventing and treating diseases mediated by the SSAO/VAP-1 protein.

Career Highlights

Frank Wu has worked with several notable companies throughout his career. He has been associated with Nanjing Transthera Biosciences Co. Ltd. and Ford Global Technologies, LLC. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.

Collaborations

Frank Wu has collaborated with several professionals in his field, including Lin Li and Xiaoju Yang. These collaborations have further enhanced his research and development efforts in pharmaceuticals.

Conclusion

Frank Wu is a distinguished inventor whose work in pharmaceuticals has led to significant advancements in treating heart failure and related diseases. His innovative patents and collaborations reflect his commitment to improving medical treatments and patient outcomes.

Profile summary based on public USPTO records.